HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $237

HC Wainwright & Co. analyst Andrew S. Fein has maintained a Buy rating on Biogen (NASDAQ: BIIB) and increased the price target from $228 to $237. This adjustment reflects a positive outlook on the company's performance.